(ATOMICC) A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients with High-risk Locally Advanced Cervical Cancer After Chemo-radiation (34) NCT03833479. Here, PDCD1 is linked to cervical cancer.